Drug makers say they have valid business reasons for the price increases. Critics say the industry is trying to establish a higher price base before Congress passes legislation that tries to curb drug spending in coming years.
"When we have major legislation anticipated, we see a run-up in price increases," says Stephen W. Schondelmeyer, a professor of pharmaceutical economics at the University of Minnesota. He has analyzed drug pricing for AARP, the advocacy group for seniors that supports the House health care legislation that the drug industry opposes.
Read the rest at: NYTimes.com
For more news like this go to NoAgendaShow.com and Gitmo Nation Roundtable.
For lively discussion on this topic and more go to NoAgendaForums.com and NoAgendaChat.com.